Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 10, 2025

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has …

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication …

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, …

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and …

Dr. Mahmoud Aljurf, First Non-US Physician to win Weinberger Prize by American College of Physicians
RIYADH, Saudi Arabia, April 10, 2025 (GLOBE NEWSWIRE) -- Dr. Mahmoud Aljurf, M.D., MACP, Director of the Adult Stem Cell Transplantation and Cellular Therapy Program King Faisal Specialist Hospital …

Merakris Therapeutics Appoints Roger Ilagan to Chief Scientific Officer
RESEARCH TRIANGLE PARK, N.C., April 10, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics has named Roger Ilagan, PhD as its new Chief Scientific Officer (CSO). Responsible for guiding the biologic drug development of first-in-class wound care technology that …

The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 10 APRIL 2025 at 13.15 EEST The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a …

Helsingin hovioikeus tuomitsi Orionin hallituksen jäsenen sakkorangaistukseen arvopaperimarkkinoita koskevasta tiedottamisrikoksesta
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 10.4.2025 KLO 13.15 Helsingin hovioikeus tuomitsi Orionin hallituksen jäsenen sakkorangaistukseen arvopaperimarkkinoita koskevasta …

Keros Therapeutics Announces Review of Strategic Alternatives
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on …

Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and …

Neue Imprivata Studie: Mehr als die Hälfte aller befragten deutschen Unternehmen von Cybervorfällen aus der Lieferkette betroffen
LANGENFELD, Deutschland, April 10, 2025 (GLOBE NEWSWIRE) -- Eine Studie des Ponemon Institutes gemeinsam mit Imprivata ergab, dass 51 Prozent der befragten deutschen Unternehmen einen Datenverlust oder eine Cyberattacke als Folge eines …

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation …